Venetoclax-azacitidine as salvage therapy for relapsed mixed phenotype acute leukemia after a second allogeneic hematopoietic stem cell transplantation: a case report.
Sabrine Mekni, Rimmel Yosra Kanoun, Saloua Ladeb, Dorra Belloumi, Nour Ben Abdeljelil, Tarek Ben Othman
{"title":"Venetoclax-azacitidine as salvage therapy for relapsed mixed phenotype acute leukemia after a second allogeneic hematopoietic stem cell transplantation: a case report.","authors":"Sabrine Mekni, Rimmel Yosra Kanoun, Saloua Ladeb, Dorra Belloumi, Nour Ben Abdeljelil, Tarek Ben Othman","doi":"10.5045/br.2023.2023061","DOIUrl":null,"url":null,"abstract":"TO THE EDITOR: Mixed phenotype acute leukemia (MPAL) is rare, accounting for approximately 1–4% of acute leukemia (AL) cases [1]. Induction therapy for these cases is often based on acute lymphocytic leukemia (ALL) treatment protocols, followed by allogeneic stem cell transplantation (ASCT). However, post-ASCT relapse after ASCT remains the primary cause of treatment failure. The median overall survival (OS) of patients who relapse after ASCT is extremely poor, with a median 3-year survival rate ranging between 9% and 11% [2]. Recent studies have reported better survival rates with a combination of venetoclax (VEN) and hypomethylating agents (HMA). Here, we describe the case of a 36-year-old patient with B/T MPAL who developed medullary relapse after 2 ASCTs and was successfully treated with VEN and azacitidine (VEN-AZA).","PeriodicalId":46224,"journal":{"name":"Blood Research","volume":null,"pages":null},"PeriodicalIF":2.3000,"publicationDate":"2023-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/28/08/br-58-2-118.PMC10310488.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Blood Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5045/br.2023.2023061","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
TO THE EDITOR: Mixed phenotype acute leukemia (MPAL) is rare, accounting for approximately 1–4% of acute leukemia (AL) cases [1]. Induction therapy for these cases is often based on acute lymphocytic leukemia (ALL) treatment protocols, followed by allogeneic stem cell transplantation (ASCT). However, post-ASCT relapse after ASCT remains the primary cause of treatment failure. The median overall survival (OS) of patients who relapse after ASCT is extremely poor, with a median 3-year survival rate ranging between 9% and 11% [2]. Recent studies have reported better survival rates with a combination of venetoclax (VEN) and hypomethylating agents (HMA). Here, we describe the case of a 36-year-old patient with B/T MPAL who developed medullary relapse after 2 ASCTs and was successfully treated with VEN and azacitidine (VEN-AZA).